Immupharma (IMM)

 

Latest News

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

ImmuPharma completes sharing agreement with Lanstead

ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...

All News

DateHeadlineSource
01-07-16Holding(s) in CompanyRNS
27-06-16Second Price Monitoring ExtnRNS
27-06-16Price Monitoring ExtensionRNS
20-06-16ImmuPharma appoints joint broker StockMarketWire
20-06-16Appointment of Joint BrokerRNS
09-06-16Why are Immupharma plc, Purplebricks Group plc and Roxi Petroleum plc among today’s major movers?Motley Fool
09-06-16Holding(s) in CompanyRNS
08-06-16Symposium with Lupuzors Inventor Prof. S MullerRNS
07-06-16ImmuPharma update on Lupuzor studyStockMarketWire
07-06-16Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?Motley Fool
07-06-16European Patients Commence Dosing in LupuzorRNS
02-06-16Director/PDMR ShareholdingRNS
31-05-16Holding(s) in CompanyRNS
26-05-16ImmuPharma resolutions passed at AGMStockMarketWire
26-05-16Result of AGMRNS
25-05-16Holding(s) in CompanyRNS
04-05-16ImmuPharma losses widenStockMarketWire
04-05-16Annual Financial Report & Notice of AGMRNS
04-05-16Final ResultsRNS
26-04-16ImmuPharma schedules FY results StockMarketWire
26-04-16Notice of ResultsRNS
22-04-16Holding(s) in CompanyRNS
09-03-16ImmuPharma starts European patient recruitment for Lupuzor trial StockMarketWire
09-03-16First European Site Opens - Patient RecruitmentRNS
08-03-16Holding(s) in CompanyRNS
07-03-16Holding(s) in CompanyRNS
01-03-16EIS and VCT Qualifying Status and Issue of EquityRNS
29-02-16Holding(s) in CompanyRNS
24-02-16ImmuPharma raises GBP7.7mStockMarketWire
24-02-16Issue of EquityRNS
22-02-16ImmuPharma fundraising approved StockMarketWire
22-02-16Result of GMRNS
15-02-16Dosing starts for ImmuPharma's Lupuzor trial StockMarketWire
15-02-16US PATIENTS COMMENCE DOSING IN PHASE III STUDYRNS
05-02-16ImmuPharma raises GBP8.3m via placingStockMarketWire
05-02-16Placing and Subscription Raises £8.3 millionRNS
05-02-16ImmuPharma fundraising to finance Lupuzor trial StockMarketWire
05-02-16Proposed Placing and SubscriptionRNS
21-01-16Holding(s) in CompanyRNS
15-12-15ImmuPharma update on Lupuzor StockMarketWire

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account